Welcome to our dedicated page for Resmed SEC filings (Ticker: RSMDF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Resmed's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Resmed's regulatory disclosures and financial reporting.
ResMed Inc. reported an insider stock sale by its Global General Counsel. The Form 4 shows that officer Michael J. Rider sold 50 shares of ResMed common stock on 12/01/2025 at a price of $244.16 per share. After this transaction, he beneficially owned 9,791 shares of ResMed common stock directly.
The filing notes that the sale was made under a pre-arranged Rule 10b5-1 trading plan that was adopted on February 28, 2025, which is designed to allow insiders to sell shares according to a set schedule.
ResMed Inc.'s Chief Financial Officer reports a routine stock sale. On 12/01/2025, the CFO sold 1,000 shares of ResMed common stock at a price of $244.16 per share in an open market transaction. The filing notes that this sale was conducted under a pre-arranged Rule 10b5-1 trading plan that was adopted on February 19, 2025, which is designed to allow insider transactions under preset instructions.
After this transaction, the CFO continues to beneficially own 87,495 ResMed shares, held directly. The filing does not report any derivative securities transactions, indicating that this update relates only to common stock ownership.
An insider of RMD has filed a notice to sell 1,000 shares of common stock through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $244,160. These shares were acquired on 11/11/2022 through restricted stock vesting as compensation from the issuer.
In the past three months, the same seller reported three additional sales: 3,000 shares on 09/02/2025 for gross proceeds of $812,310, 3,000 shares on 10/01/2025 for $823,080, and 3,000 shares on 11/03/2025 for $742,620. The issuer lists 145,966,294 shares of common stock outstanding, providing scale versus these planned and recent insider sales.
ResMed Inc. insider plans sale of common shares under Rule 144. The notice covers a proposed sale of 2,055 common shares through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $524,025.00. The issuer has 145,966,294 common shares outstanding. The shares derive from restricted stock vesting awards granted as compensation on 11/11/2021 and 11/11/2024.
During the past three months, the same seller, Jan De Witte, sold 487 common shares on 11/11/2025 for gross proceeds of $121,871.75. By signing the notice, the seller represents that he does not know any material adverse information about ResMed’s current or prospective operations that has not been publicly disclosed.
ResMed Inc. director activity: A company director reported option exercises and related share dispositions in ResMed Inc. common stock. On 11/14/2025, the director exercised 11,442 stock options at an exercise price of $101.64 per share, adding 11,442 shares to their direct holdings. On the same date, 7,314 shares were disposed of at $244.46 per share to cover tax withholding and the cost to exercise options originally granted on 11/14/2018. After these transactions, the director directly owned 70,238 shares of ResMed common stock, and the reported option grant covering 11,442 shares was fully exercised, leaving 0 derivative securities from that grant.
ResMed Inc. (RMD) filed a Form 4 reporting a routine insider transaction by director Harjit Gill. On 11/11/2025, 38.209 shares of ResMed common stock were disposed of under transaction code F at a $250.1 price to cover taxes upon vesting of previously granted RSUs. Following this withholding event, Gill beneficially owns 9,867 shares, held directly. The filing notes the RSUs were originally granted on 11/20/2024. This reflects administrative tax withholding rather than an open‑market sale.
ResMed Inc. (RMD) director Mr. Farrell reported two recent stock transactions. On 11/11/2025, he disposed of 162.953 shares of ResMed common stock at $250.10 per share, sent back to the company to cover taxes on the vesting of restricted stock units granted on 11/20/2024. On 11/12/2025, he sold 2,000 shares of ResMed common stock at an average price of $252.05 per share in an open-market transaction. After these actions, he beneficially owns 66,110 shares directly. The sale on 11/12/2025 was made under a Rule 10b5-1 trading plan adopted on August 12, 2025.
ResMed Inc. (RMD) Chairman and CEO Michael Farrell, who is also a director, reported routine share dispositions related to tax withholding on restricted stock unit (RSU) vesting. On 11/11/2025, he disposed of 2,231.545, 3,459.325, and 2,205.697 shares of ResMed common stock back to the issuer at a price of $250.1 per share, each coded "F" to indicate they were withheld for taxes upon RSU vesting from grants dated 11/16/2022, 11/16/2023, and 11/16/2024. After these transactions, Farrell beneficially owned 459,969 ResMed shares directly and 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust.
ResMed Inc. director Jan De Witte reported stock transactions in company shares. On 11/11/2025, he sold 487 shares of ResMed common stock at $250.25 per share under a pre-arranged Rule 10b5-1 trading plan adopted on Feb 03, 2025. On the same date, 76.449 shares were disposed of to the issuer to cover tax withholding tied to the vesting of previously granted restricted stock units from 11/20/2024. After these transactions, he directly owned 5,242 shares of ResMed common stock.
ResMed Inc. (RMD) reported an insider transaction by Michael J. Rider, Global General Counsel, on 11/11/2025. The filing shows issuer share withholdings for taxes upon RSU vesting (transaction code F).
Withholdings were 135.075, 173.725, 715.489, and 500.735 shares of common stock at $250.1 per share, tied to RSU grants dated 11/18/2021, 11/16/2022, 11/16/2023, and 11/20/2024. After these transactions, Rider beneficially owned 9,841 shares directly. Holdings include 38.9396 shares acquired on 10/31/2025 through the ResMed Employee Stock Purchase Plan.